HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management.
about
Leucoreduction of blood components: an effective way to increase blood safety?Improving platelet transfusion safety: biomedical and technical considerationsCurrent trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibilityLaboratory testing for platelet antibodiesTransfusion as an Inflammation Hit: Knowns and UnknownsThe mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness.Anti-HLA alloantibodies in surgical patients refractory to platelet transfusionFrequency of human platelet antigens (HPA)-1, -2, -5 and -15 in Brazilian blood donors and establishment of a panel of HPA-typed donors.Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions.Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions.Simultaneous human platelet antigen genotyping and detection of novel single nucleotide polymorphisms by targeted next-generation sequencing.The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation.State of the art in platelet function testing.A novel strategy for the screening for platelet refractoriness: prospects and limitations.Platelet antibody detection by flow cytometry: an effective method to evaluate and give transfusional support in platelet refractorinessBlood Product Supply in Germany: The Impact of Apheresis and Pooled Platelet Concentrates.Adverse effects of transfusion.A future with less HLA: potential clinical applications of HLA-universal cells.Clinical Role of Human Leukocyte Antigen in Health and Disease.Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.Platelet donor selection for HLA-immunised patients; the impact of donor-specific HLA antibody levels.Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients.Red blood cell antigen alloimmunization: Mysteries still unsolvedHuman platelet antigen genotyping of platelet donors in southern Brazil.Role of donor and recipient sex in platelet transfusion.Standardized genotyping of HLA STR by CE as surrogate for HLA class I and II markers and for identification of HLA identical siblings.Blood and Blood Components: From Similarities to Differences.Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.Applicability of an instrument to identify human leukocyte antigen-compatible donors for platelet transfusionsA subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation
P2860
Q26771857-1C998B08-06A5-4A91-B9CB-2109A45C4F6BQ26775408-9AAD7C35-5B00-49C3-A074-8D8FE5FCE8B2Q26784256-DC4F5873-749B-4FF2-9270-69942DA0164CQ27006810-6FE34984-9AF8-4AC3-B923-D7F19B0A97F4Q28074933-DD30FA87-73D5-4AB4-AE02-17A52AE08F3DQ33407537-893B462F-189B-4497-920F-F655AAA1D5B2Q33415207-2A1E18B7-0E87-4D5D-ACA9-1CF83E5D8851Q33423285-BAAFEEF4-8840-413C-8A57-4D30081BF232Q33426157-88A3C4D8-679F-4746-85CE-F842D74881A3Q33432719-19442B7F-C670-43ED-B2E4-5783C524D735Q33440638-B8E02DA6-F3FE-4FDD-A7DD-4FADC8F2F187Q36766478-A52A888D-8858-41BD-8775-0416E79F3EE3Q36802971-CF192C91-590D-4132-AD3B-0A735535CC5AQ37212588-3EB58D90-9635-4C09-8781-44D728F2A524Q37212610-DCDF0A07-F5D2-4426-A968-53FE0C276804Q37508075-C8DF98CD-8BF3-4868-A774-1CC61C8C15ADQ38287593-0C05F37B-1E08-4571-A792-8897217EED44Q38416517-166A4D5E-B601-4037-A136-54D378BBC367Q38534421-4F0E1DFA-4D1C-4075-B28C-176028326B43Q38551094-D2C45C53-8AF6-47E1-9A89-91269CBCECC1Q40262642-BBF423A2-31C7-4328-9383-1E6C21B6F0D6Q41143384-A44CF22F-C372-47E6-95AB-C89B52670791Q42382332-205CFDD6-FF46-439C-919D-344D3367CADEQ48154312-02543371-CDAC-4BE5-B09F-A995389BFD95Q50494399-F7414300-8607-4455-841D-73ACCD4D925CQ53185262-02944580-3B55-417F-8DB9-AAB6ED61790DQ55071073-EDA2CA09-A6F1-4028-9A65-3F4A399BC38CQ55397497-F9391926-351D-4FF0-A62E-069640145D26Q58124890-3DE819A1-C515-42F0-956D-01204EBD1257Q58793864-4C88B842-7427-490A-8F63-6D9C0FD8EB29
P2860
HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
HLA alloimmunization against p ...... ce, prevention and management.
@en
HLA alloimmunization against p ...... ce, prevention and management.
@nl
type
label
HLA alloimmunization against p ...... ce, prevention and management.
@en
HLA alloimmunization against p ...... ce, prevention and management.
@nl
prefLabel
HLA alloimmunization against p ...... ce, prevention and management.
@en
HLA alloimmunization against p ...... ce, prevention and management.
@nl
P2093
P2860
P1433
P1476
HLA alloimmunization against p ...... ce, prevention and management.
@en
P2093
J W Semple
John Freedman
Katerina Pavenski
P2860
P304
P356
10.1111/J.1399-0039.2012.01852.X
P577
2012-04-01T00:00:00Z